Literature DB >> 21734918

Paroxysmal hemicrania responding to topiramate.

A S Cohen1, P J Goadsby.   

Abstract

Chronic paroxysmal hemicrania (CPH) is a rare primary headache syndrome, which is classified along with cluster headache and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) as a trigeminal autonomic cephalalgia. CPH is exquisitely responsive to indomethacin, so much so that the response is one of the current diagnostic criteria. The case of a patient with CPH, who had marked epigastric symptoms with indomethacin treatment and responded well to topiramate 150 mg daily, is reported. Cessation of topiramate caused return of episodes, and the response has persisted for 2 years. Topiramate may be a treatment option in CPH.

Entities:  

Year:  2009        PMID: 21734918      PMCID: PMC3027924          DOI: 10.1136/bcr.06.2009.2007

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  33 in total

1.  Topiramate relieves refractory trigeminal neuralgia in MS patients.

Authors:  M Zvartau-Hind; M U Din; A Gilani; R P Lisak; O A Khan
Journal:  Neurology       Date:  2000-11-28       Impact factor: 9.910

2.  Episodic paroxysmal hemicrania responsive to calcium channel blockers.

Authors:  F Coria; L E Claveria; F J Jimenez-Jimenez; E V de Seijas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-02       Impact factor: 10.154

3.  Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study.

Authors:  I Gilron; S L Booher; J S Rowan; M B Max
Journal:  Clin Neuropharmacol       Date:  2001 Mar-Apr       Impact factor: 1.592

Review 4.  Topiramate in migraine prevention.

Authors:  Stephen D Silberstein
Journal:  Headache       Date:  2005-04       Impact factor: 5.887

5.  Treatment of cluster headache with topiramate: effects and side-effects in five patients.

Authors:  S Förderreuther; M Mayer; A Straube
Journal:  Cephalalgia       Date:  2002-04       Impact factor: 6.292

6.  Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the 'indotest'.

Authors:  F Antonaci; J A Pareja; A B Caminero; O Sjaastad
Journal:  Headache       Date:  1998-02       Impact factor: 5.887

7.  Hemicrania continua responds to cyclooxygenase-2 inhibitors.

Authors:  Mario F P Peres; Stephen D Silberstein
Journal:  Headache       Date:  2002-06       Impact factor: 5.887

8.  The paroxysmal hemicrania-tic syndrome.

Authors:  C J Boes; M S Matharu; P J Goadsby
Journal:  Cephalalgia       Date:  2003-02       Impact factor: 6.292

9.  Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control.

Authors:  Hans-Christoph Diener; Peer Tfelt-Hansen; Carl Dahlöf; Miguel J A Láinez; Giorgio Sandrini; Shuu-Jiun Wang; Walter Neto; Ujjwalla Vijapurkar; Aiden Doyle; David Jacobs
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

10.  Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate.

Authors:  Ninan T Mathew; Jayasree Kailasam; Lori Meadors
Journal:  Headache       Date:  2002-09       Impact factor: 5.887

View more
  1 in total

Review 1.  When indomethacin fails: additional treatment options for "indomethacin responsive headaches".

Authors:  Shuhan Zhu; Brian McGeeney
Journal:  Curr Pain Headache Rep       Date:  2015-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.